NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 47

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Vincent Hospital & Health Center	In accordance with letter dated September 25, 1992 3. License number 25-07553-01 is amended in its entirety to read as follows:
2. P.O. Box 35200 Billings, Montana 59107	4. Expiration date April 30, 1994
	5. Docket or Reference No 030-02396

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct materialidentified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300 35.300	C. Any radiopharmaceutical identified in 10 CFR	C. As needed
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources for diagnostic devices identified in 10 CFR 35.500	E. 2 curies per source
F. Any byproduct material	F. Prepackaged Kits	F. As needed identified in 10 CFR 31.11

12/14/92

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 25-07553-01

Docket or Reference number: 030-02396

Amendment No. 47

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.
B. Medical use described in 10 CFR 35.200.
C. Medical use described in 10 CFR 35.300.
D. Medical use described in 10 CFR 35.400 and, for Cesium-137, for calibration of licensee's survey meters and personnel dosimeters.
E. Medical use described in 10 CFR 35.500.
F. In vitro studies.

CONDITIONS

10. Location of use: 1233 North 30th Street, Billings, Montana.

11. Radiation Safety Officer: Jon A. Anderson, M.D.

12. Authorized Users:

A. Fred A. Deigert, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11.

B. Wiley R. Bland, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.

C. Jon A. Anderson, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.

D. E. Stewart Taylor, M.D., for material identified in 10 CFR 35.100, 35.200, 35.500 and 31.11.

E. James T. Griffin, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400 and 35.500.

F. John V. Hanson, M. D., for material identified in 10 CFR 35.100, 35.200, 35.500 and 31.11.

G. James K. Vincent, M.D., for material identified in 10 CFR 35.200 for cardiovascular clinical procedures 35.500 and 31.11.

H. Walter C. Degnan, M.D., for material identified in 10 CFR 35.200 for cardiovascular clinical procedures, 35.500 and 31.11.

I. Mitchell E. Gallagher, M.D., for material identified in 10 CFR 35.100, 35.200, 35.500 and 31.11.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 25-07553-01

Docket or Reference number 030-02396

Amendment No. 47

12. (Continued)

J. John Gerard Terry, M.D., for material identified in 10 CFR 35.300, 35.400, and 35.500.

K. Hoyle Setzer, M.D., for material identified in 10 CFR 31.11.

L. Frank Robert Lamm, M.D., for material identified in 10 CFR 35.300, 35.400, and 35.500.

M. Walter G. Gunn, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500, and 31.11.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee shall maintain records of information important to safe and effective decommissioning at St. Vincent Hospital & Health Center, 1233 North 30th Street, Billings, Montana, per the provision of 10 CFR 30.35(g) until this license is terminated by the Commission.

15. This license is based on the licensee's statements and representations as follows:

A. Application dated November 12, 1988
B. Letter dated March 28, 1989
C. Letter dated April 23, 1992
D. Letter dated September 25, 1992

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date DEC 8 1992

By Original Signed By
Vivian H. Campbell
Nuclear Materials Licensing Section
Region IV
Arlington, Texas 76011

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-8064

DEC 8 1992

Saint Vincent Hospital and Health Center
ATTN: Jon Anderson, M.D.
Radiation Safety Officer
P. O. Box 35200
Billings, Montana 59107-5200

Gentlemen:

Please find enclosed Amendment No. 47 to your NRC materials license. You should review this amendment carefully and be sure that you understand all conditions. If you have any questions, you may contact the reviewer who signed your license amendment at 817/860-8100.

Please be advised that you must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Possess radioactive material only in the quantity and form indicated in your license.

3. Use radioactive material only for the purpose(s) indicated in your license.

4. Notify NRC in writing of any change in mailing address (no fee required if the location of radioactive material remains the same).

5. Request and obtain written NRC consent before transferring your license or any right thereunder, either voluntarily or involuntarily, directly or indirectly, through transfer of control of your license to any person or entity. A transfer of control of your license includes not only a total change of ownership, but also a change in the controlling interest in your company whether it is a corporation, partnership, or other entity. In addition, appropriate license amendments must be requested and obtained for any other planned changes in your facility or program that are contrary to your license or contrary to representations made in your license application, as well as supplemental correspondence thereto, which are incorporated into your license. A license fee may be charged for the amendments if you are not in a fee-exempt category.

6. Submit a complete renewal application with proper fee, or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material.

You will be periodically inspected by NRC. A fee may be charged for inspections in accordance with 10 CFR Part 170. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Action, 10 CFR Part 2, Appendix C. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which the NRC expects of its licensees.

Thank you for your cooperation.

Sincerely,

Billie Gruszynski

Billie Gruszynski (Ms.)
Nuclear Materials Licensing Section

Enclosure:
As stated

RIV:NMLS
BRGruszynski
12/3/92

RIV:NMLS
VHCampbell
12/7/92

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19940430
FEE COMMENTS: CODE 21
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: ST. VINCENT HOSP. & HEALTH CTR.
RECEIVED DATE: 921014
DOCKET NO: 3002396
CONTROL NO.: 464444
LICENSE NO.: 25-07553-01
ACTION TYPE: AMENDMENT

DEC 2 1992

2. FEE ATTACHED
AMOUNT: $430.00
CHECK NO.: 105258

3. COMMENTS

SIGNED Billie Gruszynski
DATE 12/15/92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED (√))

1. FEE CATEGORY AND AMOUNT: 7C $430+$0

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT √
RENEWAL
LICENSE

3. OTHER

SIGNED
DATE 11-30-92

Saint Vincent Hospital and Health Center

September 25, 1992

United States Nuclear Regulatory Commission
Region IV
611 Ryan Plaza, Suite 1000
Arlington, TX 76011

RE: Amendment to License Number 25-07553-01

Gentlemen:

Please amend our Byproducrt Materials License to include Doctor John Gerald Terry for Groups 35.300, 35.400, and 35.500. In support of this request please find enclosed a copy the Iowa Department of Public Health license (Number 0046-2-07-M1) listing Dr. Terry as an authorized user for Groups IV,V and VI and a copy of his American Board of Radiology Certification in Radiation Oncology.

Saint Vincents Hospital requests the NRC to update its license to reflect the list authorized users to include only those in active practice at this time. Please remove from the list of authorized users: Dr. Guy Glenn and Dr. Colvin Agnew.

Please find enclosed check for $430.00 to cover the fee for this amendment request.

Sincerely,

Dr. Jon Anderson
Radiation Safety Officer

Post Office Box 35200
Billings, Montana 59107-5200
406-657-7600

We touch your life.

RECEIVED
1992 OCT 20 AM 8:42

Log 082 IV
Remitter St Vincent Hospital
Check No. 105258 102399
Amount $430 $430
Fee Category 2A
Type of Fee AMD
Date Check Rec'd 10/20/92 11/30/92
Date Completed 11/30/92
By: DC

464444

MATERIALS LICENSE

Pursuant to Chapter 136C of the Iowa Code and 641-38 through 42 (136C) of the Iowa Administrative Code and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer radioactive materials designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the rules of the applicable chapter(s). This license is subject to all applicable rules and orders of the Iowa Department of Public Health including the Iowa Rules for Radiation Machines and Radioactive Materials [641-38 through 42] now or hereafter in effect, and to any conditions specified below.

Licensee	In accordance with application dated February 27, 1990, License No. 0046-2-07-M1 is renewed to read as follows:
1. Covenant Medical Center	
2. 200 East Ridgeway Waterloo, Iowa 50702	3. License Number: 0046-2-07-M1
	4. Expiration Date: March 31, 1995

5. Byproduct, Source, Special Nuclear and/or Natural Occurring or Accelerator Produced Radioactive Material	6. Chemical and/or Physical Form	7. Maximum Amount that Licensee May Possess at any One Time Under This License
A. Any radioactive material listed in Groups I and II of 641-39.74 (136C)	A. Any radiopharmaceutical in Groups I and II of 641-39.74(136C)	A. As necessary for uses authorized in Subitem 8. A.
B. Any radioactive material listed in Group III of 641-39.74(136C)	B. Any form listed in Group III of 641-39.74(136C)	B. Two curies of each radioactive material authorized in Subitem 5. B.
C. Any radioactive material listed in Group IV of 641-39.74(136C)	C. Any radiopharmaceutical listed in Group IV of 641-39.74(136C)	C. As necessary for uses authorized in Subitem 8. C
D. Any radioactive material listed in Group V of 641-39.74(136C)	D. Any radiopharmaceutical listed in Group V of 641-39.74(136C)	D. As necessary for uses authorized in Subitem 8. D.

E.	Any radioactive material listed in Group VI of 641-39.74(136C)	E. Any sealed source listed in Group VI of 641-39.74(136C)	E. 2500 millicuries for sources with half lives greater than 65 days. As needed for sources with half lives less than 65 days.
F.	Any radioactive material listed in 641-39.25 (136C)	F. Prepackaged kits	F. Three millicuries of each type of material authorized in Subitem 5. F.
G.	Cobalt-57	G. Any sealed source manufactured, packaged and distributed in accordance with a specific license issued pursuant to 641-39.44(136C) or a specific license issued to the manufacturer by another Agreement State, a licensing state or the U.S. Nuclear Regulatory Comission.	G. No single source to exceed 15 millicuries.
H.	Cobalt-57	H. Any flood source manufactured,packaged and distributed in accordance with a specific license issued pursuant to 641-39.44(136C) or a specific license issued to the manufacturer by another Agreement State, a licensing state, or the U.S. Nuclear Regulatory Comission.	H. No single source to exceed 15 millicuries.
I.	Uranium (Depleted in Uranium 235)	I. Cadmium plated metal	I. 350 kilograms.

J. Indium-111	J. Pentetate sodium	J. As necessary for uses authorized in Subitem 8. J.
K. Palladium-103	K. Sealed source(s)	K. As necessary for uses authorized in Subitem 8. K.
L. Technetium-99m	L. Albumin colloid	L. As necessary for uses authorized in Subitem 8. L.
M. Technetium-99m	M. Pentetate sodium	M. As necessary for uses authorized in Subitem 8. ...

8. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of 641-39.74(136C).

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of 641-39.74(136C).

C. Any therapeutic procedure listed in Group IV of 641-39.74(136C).

D. Any therapeutic procedure listed in Group V of 641-39.74(136C).

E. Any procedure listed in Group VI of 641-39.74(136C).

F. In vitro studies.

G. To be used for standardization and quality assurance of dose calibrator and other radiation detection instrumentation.

H. To be used for quality assurance of nuclear medicine imaging equipment.

I. To be used as shielding in a linear accelerator.

J. To be used in radionuclide cisternography.

K. To be used for interstitial treatment of cancer.

L. To be used for spleen and liver scans in nuclear medicine.

M. To be used for lung ventilation scans in nuclear medicine.

CONDITIONS

9. Licensed material shall be used only at the licensee's facilities located at 2101 Kimball Avenue, 200 East Ridgeway, and 3421 West 9th Street, Waterloo, Iowa.

10. Licensed material listed in Item 5 above is authorized for use by the following individual(s) for the materials and uses indicated:

Gerald M. Verdobelde, M.D.	Groups I, II, III, IV, and V. Gadolinium-153 for bone mineral analysis. Iodine-125 for bone mineral analysis. In vitro studies. Indium-111 as pentetate sodium. Technetium-99 as albumin colloid or pentetate sodium.
Robert M. Guthrie, M.D.	Groups IV, V, and VI. Palladium-103 for interstitial treatment of cancer.
Clarence J. Ludwig, M. D.	Groups I and IV, except Phosphorus-32. Radium-226.
David N. Koury, M.D.	Groups I, II, and III. Gadolinium-153 for bone mineral analysis. Iodine-125 for bone mineral analysis. In vitro studies. Indium-111 as pentetate sodium. Techetium-99m as albumin colloid or pentetate sodium.
James V. Connell, M.D.	Groups I, II, and III. Gadolinium-153 for bone mineral analysis. Iodine-125 for bone mineral analysis. In vitro studies. Indium-111 as pentetate sodium. Technetium-99m as albumin colloid or pentetate sodium.

MATERIALS LICENSE

Supplementary Sheet

License Number: 0046-2-07-M1

John G. Terry, M.D.	Groups IV, V, and VI. Palladium-103 for interstitial treatment of cancer.
V. P. Hooyman, M. D.	Groups I, II, and III. Gadolinium-153 for bone mineral analysis. Iodine-125 for bone mineral analysis. In vitro studies. Indium-111 as pentetate sodium. Technetium-99 as albumin colloid or pentetate sodium.

11. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's administrator and its Medical Isotopes Committee.

    B. Is specifically named as a user on an Agency, U.S. Nuclear Regulatory Commission, or another Agreement State license authorizing human use.

    C. Performs only those procedures for which he is specifically authorized by the Agency, U.S. Nuclear Regulatory Commission, or another Agreement State.

    The licensee shall maintain for inspection by the Agency, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above for a period of five (5) years from the time the licensee grants its permission under Subitem A above.

12. Licensed material shall be used in accordance with the provisions of 641-39.31(3)b, c, e, and f.

13. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

14. Patients containing Cobalt 60, Cesium 137, Iridium 192, or Radium 226 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Agency for five (5) years from the time the implants are removed.

15. The licensee shall establish a bioassay program for individuals handling millicurie amounts of Iodine-131 in accordance with frequencies and procedures contained in U.S. Nuclear Regulatory Commission's (NRC) Regulatory Guide 8.20, "Applications of Bioassay for I-125 and I-131."

16. The licensee shall conduct a physical inventory every six (6) months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for two (2) years from the date of the inventory for inspection by the Agency, and shall include the quantities and kinds of radioactive material, manufacturer's name and model numbers, location of sealed sources, and the date of the inventory.

17. A. (1) The source(s) specified in Subitem(s) 6. K. and Group VI shall be tested for leakage and/or contamination at intervals not to exceed six months. Any source received from another person which is not accompanied by a certificate indicating that a test was performed within six months before the transfer shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. Any source in storage and not being used need not be tested. When the source is removed from storage for use or transfer to another person, it shall be tested before use or transfer.

C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source shall be removed from service and decontaminated, repaired, or disposed of in accordance with Agency rules. A report shall be filed within five days of the date the leak test result is known with the Bureau of Radiological Health, Iowa Department of Public Health, Lucas State Office Building, Des Moines, Iowa 50319-0075. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Agency. Records may be disposed of following Agency inspection.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Agency, U.S. Nuclear Regulatory Commission, or another Agreement State to perform such services.

18. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

    B. Before disposal as norma waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

19. The licensee shall keep records of and report all misadministrations of radioactive materials as specified in 641-40.20(4) of Iowa's rules for radioactive materials, effective January 6, 1988.

20. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Iowa Department of Public Health's rules shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the rules.

    A. Application dated February 27, 1990, (with attachments).

For the Iowa Department of Public Health

Date 4-10-90

By Donald A. Flater
Donald A. Flater, Chief
Bureau of Radiological Health

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology,
and the Association of University Radiologists
Hereby certifies that

John Gerard Terry, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this seventh day of June, 1990
Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Radiation Oncology

Robert G Parker

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

AMERICAN BOARD

OCT 28 1992

LICENSE FILE

St. Vincent Hospital [redacted]ealth Center
Attn: Dr. Jon Anderson, R.S.O.
P.O. Box 35200
Billings, MT 59107-5200

Gentlemen:

This refers to your letter dated September 25, 1992, for an amendment to Materials License 25-07553-01.

We received your check for $430. Your request, however, is subject to an amendment fee of $460 as specified in fee Category 7C of §170.31, 10 CFR 170, which went into effect August 24, 1992. A copy of the July 24, 1992, **Federal Register** notice regarding the revisions to the Commission's license and annual fee regulations (10 CFR 170 and 10 CFR 171) is enclosed.

Please note that effective August 24, 1992, materials licensees are also subject to the annual fees specified in revised 10 CFR 171. Payment of the additional $30 fee should be made to the U.S. Nuclear Regulatory Commission and mailed to the following address:

U.S. Nuclear Regulatory Commission
ATTN: Marnella Rodriguez
License Fee and Debt Collection Branch, OC/DAF
Mail Stop MNBB 4503
Washington, DC 20555

Your application will be processed by the Region IV Licensing staff located at 611 Ryan Plaza Drive, Suite 1000, Arlinton, Texas 76011. The fee, however, is required prior to issuance of the amendment. When submitting the additional fee, please refer to CONTROL NUMBER 464444.

If we do not receive a reply from you within 30 calendar days from the date of this letter, we shall assumo that you do not wish to pursue your application and will void this action.

Sincerely,

/S/

Marnella Rodriguez
License Fee and Debt Collection Branch
Division of Accounting and Finance
Office of the Controller

Enclosure:
July 23, 1992, **Federal Register** notice

cc: Region IV

DISTRIBUTION
Pending Fee File
OC/DAF R/F
LFDCB R/F (2)

OFFICE:	OC/LFDCB	OC/LFDCB
NAME:	MRodriguez	MMessier
DATE:	10/27/92	10/27/92

JIM2\B:SVH.MER